ArticlePediatric surgery international2026
Impact of primary tumor resection on survival in high-risk neuroblastoma: a long-term single-center study.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe prognostic value of primary tumor resection in high-risk neuroblastoma (HrNB) remains controversial. While several Western studies have suggested a survival benefit of complete resection, our institution has not observed a clear association. We therefore evaluated the long-term impact of surgical resection, particularly the extent of resection, in HrNB over four decades.
methodsWe retrospectively reviewed 64 consecutive patients with HrNB treated at our center between 1985 and 2023. Patients were classified into complete resection and incomplete/no resection groups. In the more recent cohort (2007-2023), outcomes were also compared between patients who underwent resection and those who did not. Overall survival (OS) and causes of death were analyzed.
resultsAmong 64 patients, 11 underwent no resection, 28 incomplete resection, and 25 complete resection. Five-year OS did not differ significantly between the complete and incomplete/no resection groups (57.4% vs. 53.0%). PBSCT-stratified analyses showed similar results. In the more recent cohort (n = 34), five-year OS was comparable between non-resection and resection groups (72.0% vs. 71.5%). A > 20% reduction in primary tumor diameter after induction chemotherapy was strongly associated with better survival.
conclusionSome HrNB patients can achieve favorable survival without surgical resection, supporting individualized surgical strategies and prospective multi-institutional validation.
Indexed as
Identifiers
42742647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.